Press Releases
-
Advanced BioDesign announces first patient treated under compassionate access for ABD-3001 in relapse and refractory T-cell cell acute lymphoblastic leukemia
Lyon (France), September 4th, 2025 – Advanced BioDesign, a French clinical-stage biotechnology company focused on developing innovative therapies for treatment-resistant cancers, today announced that the…
-
Advanced BioDesign Announces Positive Interim Results from Phase 1 of the ODYSSEY Clinical Trial
Lyon (France), May 27, 2025 – Advanced BioDesign, a clinical-stage biopharmaceutical company specializing in the development of novel therapeutic approaches for resistant cancers, today announced…
-
Advanced BioDesign to present preclinical proof of concept of ABD-0171 in MSS colorectal cancer at the AACR Annual Meeting 2025
Lyon, March 28th – Advanced BioDesign announced today it will present updated results of its second generation of ALDH1 inhibitor, ABD0171, at the upcoming AACR…
-
Advanced Biodesign Announces First Patient Dosed in ODYSSEY
Lyon (France), March 4, 2025 – Advanced BioDesign, a clinical-stage pharmaceutical company specializing in the development of new therapeutic approaches to resistant cancers, is pleased…
Advanced BioDesign 